Last reviewed · How we verify
Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation
This study was designed to investigate the efficacy and safety of neoadjuvant Toripalimab (anti-PD1) plus chemotherapy for patients with resectable II-IIIB non-squamous NSCLC harboring EGFR mutation, and to explore the potential predictive and prognostic biomarkers, aiming to provide more abundant evidences for the preoperative treatment decision of non-squamous NSCLC patients.
Details
| Lead sponsor | Peking University People's Hospital |
|---|---|
| Phase | PHASE2 |
| Status | NOT_YET_RECRUITING |
| Enrolment | 126 |
| Start date | Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Jun 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Non Squamous Non Small Cell Lung Cancer
- EGFR Positive Non-small Cell Lung Cancer
Interventions
- Toripalimab plus Chemotherapy